Methods for use of TSLP and agonists and antagonists thereof

Details Methods for use of TSLP and agonists and antagonists thereof Methods for use of TSLP and agonists and antagonists thereof

2007-06-13

2010-06-08

Juedes, Amy E (Department: 1644)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C435S372300

Reexamination Certificate

active

07731953

ABSTRACT:
Methods are disclosed herein for specifically inducing proliferation of CD4+T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein. The somatic and germ cells of these mice include a disrupted thymic stromal lymphopoietin receptor (TSLP) gene, the disruption being sufficient to inhibit the interaction of TSLP with its receptor, and a disrupted γcgene, the disruption being sufficient to reduce signaling through the γc. The mice exhibit diminished thymic cellularity. Methods of using these mice for drug screening are also disclosed.

REFERENCES:
patent: 6555520 (2003-04-01), Sims et al.
patent: 2003/0186875 (2003-10-01), De Waal Malefyt et al.
patent: 2007/0020262 (2007-01-01), De Waal Malefyt et al.
patent: WO 00/29581 (2000-05-01), None
patent: WO 02/068646 (2002-09-01), None
patent: WO 03/032898 (2003-04-01), None
patent: WO 03/065985 (2003-08-01), None
Burgers,2004, Best practice and Res. Clin. Obst. and Gyn. vol. 19: 277-291.
Ziegler et al., 2006, Nat. Immunol. vol. 7: 709-714.
Leonard et al., Nat. Immunol. vol. 3: 605-607.
Goldrath, 2002, Microbes and Infection. vol. 4: 539-545.
Al-Shami et al., “A role for thymic stromal lymphopoietin in CD4(+) T cell development,”J. Exp Med. 200(2), 159-168 (2004).
Busse et al.,Am. J. Respir. Crit. Care Med., 164, S12-S17 (2001).
Gilliet et al., “Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells,”J. Exp. Med. 197(8), 1059-1063 (2003).
Isaksen et al., “Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction,”J. Immunol., 168(7), 3288-3294 (2002).
Osborn et al., “Overexpression of murine TSLP impairs lymphopoiesis and myelopoiesis,”Blood, 103(3), 843-851, 2004.
Park, et al., “Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor,”J. Exp. Med., 192(5), 659-669 (2000).
Quentimeier et al., “Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation,”Leukemia, 15(8), 1286-1292 (2001).
Reche et al., “Human thymic stromal lymphopoietin preferentially stimulates myeloid cells,”J. Immunol., 167, 336-343 (2001).
Roberts et al., Eur. Respir., 14,275-282 (1999).
Rolland et al.,Expert Opinion on Investigational Drugs, 9, 515-527 (2000).
Sims et al., “Molecular cloning and biological characterization of a novel murine lymphoid growth factor,”J. Exp. Med., 192(5), 671-680 (2000).
Soumelis et al., “Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP,”Nat. Immunol., 3(7), 673-680 (2002).
Watanabe et al., “Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+T cell homeostatic expansion,”Nature Immunol., 5(4), 426-434 (2004).
Rochman et al., “Cutting Edge: Direct Action of Thymic Stromal Lymphopoietin on Activated Human CD4+T Cells,”J. Immunol., 178, 6720-6724 (2007).
Soumelis et al., “Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation,”Springer Seminars in Immunopathology, 25, 325-333 (2004).

Affiliated with

Also associated with

Rating

Methods for use of TSLP and agonists and antagonists thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for use of TSLP and agonists and antagonists thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for use of TSLP and agonists and antagonists thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4251013